Site Map Press Room Careers
Financial
Quarterly Results
Financial Highlights
Annual Reports
Business Drivers
Investors
Contact Person
Frequently Asked Questions

Unaudited Quarterly Results for the Quarter & Half year ended 30th September 2005

(Rs. in Mio)
  Three Months Ended Six Months Ended Year ended

Particulars

 (Unaudited) (Unaudited) (Audited)
  30.09.2005 30.09.2004 30.09.2005 30.09.2004 31.03.2005
Net Sales/Income from Operations 3194.8 2693.1 6001.4 5542.4 11591.7
Other Income 76.2 26.7 112.0 50.3 165.6
Total Income 3271.0 2719.8 6113.4 5592.7 11757.3
Expenditure          
a. (Increase) / Decrease in Stock in Trade
(14.6) 51.0 (139.1) (183.6) (132.4)
 b. Consumption of Raw Materials 2017.9 1423.4 3831.8 3134.3 6574.4
 c. Staff Cost 186.8 171.7 369.7 331.2 662.3
 d. Other Expenditure 789.9 800.1 1493.7 1616.8 3419.1
Total expenditure 2980.0 2446.2 5556.1 4898.7 10523.4
Profit Before Depreciation, Interest & Tax 291.0 273.6 557.3 694.0 1233.9
Interest 141.3 101.8 275.7 175.4 379.9
Depreciation 124.5 122.4 243.2 232.2 404.9
Profit before taxation 25.2 49.4 38.4 286.4 429.1
Provision for Taxation
a) Current Tax
b) Deferred Tax
c. Fringe Benefit Tax
d) Tax adjustments of previous years		 3.2
(15.1)
0.6
0.1		 7.4
7.5
8.9
 		 4.9
(24.3)
1.2
0.1		 25.2
46.2
9.2
 		 40.1
38.8
-
(0.5)
Net Profit 36.4 25.6 56.5 205.8 350.7
Paid-up Equity Share Capital 
(Face value Rs. 5/- per share)		 266.4 253.9 266.4 253.9 253.9
Reserves excluding Revaluation Reserves   --   -- 7632.0
Earnings per share (Rs.) (not annualised)          
- Basic
0.69 0.50  1.09 3.55 6.91
-Diluted
0.66 0.50 1.06 3.55 6.91
Aggregate of non-promoters Shareholding          
a. Number of Shares     23546156 22935706 229391.56
b. Percentage of Shareholding     44.20 45.18  45.18
Notes:
1. The above unaudited results which are subjected to limited review by the Auditors of the Company, were reviewed by the Audit Committee and have been taken on record by the Board at its meeting held on 29.10.2004.
2. The Company has completely written off expenses pertaining to R & D, Regulatory Plants and Bioequivalence Studies which affected the profitability in short term whereas the revenues from the regulated markets are expected in future.
3. Exports (F.O.B value) constitute Rs.1250.4 millions (Rs.1598.1 millions) of the sales for the quarter.
4. The Company's operations fall within a single primary business segment viz 'Pharmaceutical Products'.
5. Investor  complaints  pending  at  the  beginning  of  the  quarter: Nil,  received: 124,  resolved: 124 and lying unresolved at the end of the quarter: Nil. 
6. Figures for the previous periods have been rearranged/regrouped wherever necessary.
For and on behalf of the Board
Sd/-
Place: Hyderabad K.Nityananda Reddy
Date : 29.10.2004 Managing Director
Site Map Press Room Careers